News

Playing the Long Game in Lymphoma Research

Playing the long game is not a new concept for Lymphoma Research Foundation Grantee and Scientific Advisory Board (SAB) member Ari Melnick, MD, of NewYork-Presbyterian/Weill Cornell Medicine. Lymphoma research is not a field for those looking for instant gratification, but Dr. Melnick has never taken a sprinter’s approach to finding cures for lymphoma. He is more of a marathoner.

Understanding Cancer-Related Financial Toxicity

Understanding Cancer-Related Financial Toxicity Cancer is one of the costliest conditions to treat today in the United States. With outcomes among patients with lymphoma improving, managing costs related to the diagnosis and treatment of their disease is a major concern.…

Lymphoma Research Foundation Debuts New Publication: Pulse

The Lymphoma Research Foundation is proud to launch its new flagship publication, Pulse. Published quarterly, Pulse provides the latest updates on the Foundation and its focus on lymphoma and chronic lymphocytic leukemia (CLL) research, awareness and education. Pulse will also…

Lymphoma Research Foundation Elects New Board of Director Leadership

Jeff Block and Steven Eichberg Joins Lymphoma Research Foundation Board of Directors

LRF Advocates for Patient Access to Cellular Therapies

On November 2, 2019, the Lymphoma Research Foundation sent a letter to Donald Thompson, Director, Division of Acute Care at the Centers for Medicare and Medicaid Services requesting for MS-DRG reclassification for certain cases involving the use of chimeric antigen receptor T-cell (CAR T-cell) therapies.

U.S. Food and Drug Administration Approves Acalabrutinib (CALQUENCE) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).

LRF Grantee and SAB Member Discovers Protein Responsible for Lymphoma Cell Growth

A study partially funded by the Lymphoma Research Foundation, and published in the Journal of Experimental Medicine, revealed surprising new functions for a protein called MYC.

U.S. Food and Drug Administration Approves Zanubrutinib (BRUKINSA) for Mantle Cell Lymphoma (MCL)

The U.S. Food and Drug Administration (FDA) announced it has approved the use of zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least on prior therapy.

U.S. Food and Drug Administration Approves Pegfilgrastim-bmez (Ziextenzo) for Long-Acting Oncology Supportive Care

Pegfilgrastim-bmez (Ziextenzo, Sandoz) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia for patients with nonmyeloid malignancies who are receiving myelosuppressive anti-cancer therapy.

Lymphoma Research Foundation Update on Vincristine Supply

The Lymphoma Research Foundation is aware that the supply of the vital chemotherapy medicine vincristine [Oncovin] may be limited in certain areas of the country. We understand this news is very concerning to patients who receive this medicine and their…

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.